CLRO News

Gainers ClearOne (NASDAQ:CLRO) stock rose 51.3% to $5.16 during Friday's after-market session. The market value of their outstanding shares is at $13.3 million. DarkHorse Technologies (NASDAQ:DRK) shares roseread more...

Gainers Braiin (NASDAQ:BRAI) stock increased by 50.5% to $3.19 during Tuesday's pre-market session. The market value of their outstanding shares is at $436.9 million. ClearOne (NASDAQ:CLRO) shares increased byread more...

Gainers Amplitech Group, Inc. - Series B Right (NASDAQ:AMPGZ) shares rose 50.3% to $0.05 during Monday's regular session. ClearOne (NASDAQ:CLRO) shares moved upwards by 46.15% to $4.75. The company's marketread more...

The names on today’s watchlist may look familiar, but the stories are moving. NeOnc Technologies Holdings (NASDAQ:NTHI) is approaching an important FDA discussion, XIAO-I Corporation (NASDAQ:AIXI) remains a high-volatility AI stock, and BIO-key International (NASDAQ:BKYI) is adding government customers in the Gulf. Meanwhile, Bolt Biotherapeutics (NASDAQ:BOLT) announced a major acquisition and financing package, Nautilus Biotechnology (NASDAQ:NAUT) is preparing to report earnings, and AI OKTO (NASDAQ:AIOK) declared a substantial special dividend. Across communications technology with ClearOne (NASDAQ:CLRO), staffing and recruiting with Robert Half (NYSE:RHI), and satellite cybersecurity with WISeSat.Space (NASDAQ: SAIQ).

ClearOne (NASDAQ:CLRO) remained firmly on investors' radar after renewed buying interest followed a series of SEC filings that further advanced the company's pending acquisition of neurostimulation developer Cortigent. After recording its largest move since the merger was first announced on July 2, traders may continue monitoring the story as the transaction progresses toward what management has targeted as a third-quarter 2026 closing.

Gainers ClearOne (NASDAQ:CLRO) shares rose 151.6% to $9.26 during Thursday's regular session. The market value of their outstanding shares is at $9.8 million. Gauzy (NASDAQ:GAUZ) stock increased by 95.45% toread more...

ClearOne (NASDAQ CLRO), NeOnc Technologies (NASDAQ:NTHI), Iovance Biotherapeutics (NASDAQ:IOVA), and Ensysce Biosciences (NASDAQ:ENSC) are covered in today’s roundup.

The transformation of ClearOne (NASDAQ:CLRO) continues to gain momentum as the company advances its pending acquisition of neurostimulation developer Cortigent, a transaction that would fundamentally reshape the former conferencing technology company into a medical technology business focused on implantable neurostimulation devices. Following a sharp market reaction when the merger was first announced on July 2, investors again turned their attention to the story after a series of new SEC filings removed another layer of uncertainty while advancing the transaction toward completion.

ClearOne Shares surged 98.37% after hours after a key shareholder approved merger-related share issuance, advancing the Cortigent transaction.read more...